Decitabine belongs to the antineoplastic drug class and exerts cell-killing activity through interference with DNA replication, transcription, or mitosis in rapidly dividing malignant cell populations. Limited selectivity for tumour over normal proliferating tissues produces dose-limiting toxicities to bone marrow, gastrointestinal mucosa, and other high-turnover host tissues. The combination of intrinsic genotoxic potential, reproductive toxicity concern, and pharmacological potency at cellular concentrations drives the most stringent OEB classification and engineering containment requirements in pharmaceutical manufacturing.
PDE derivation for Decitabine applies the composite uncertainty factor methodology: F1 accounts for interspecies pharmacokinetic and pharmacodynamic differences (default 12 for rat-to-human, refinable with toxicokinetic AUC bridging data), F2 covers intraspecies variability in the human population including sensitive subgroups (default 10), F3 adjusts for study
